Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Equinor in connection with divestment of shares in Lundin Petroleum and investment
Mandate

Vinge advised Equinor in connection with divestment of shares in Lundin Petroleum and investment

July 12, 2019 Capital Markets and Public M&A

The Norwegian energy company Equinor ASA announced on 7 July that it had agreed with Lundin Petroleum AB (publ) to divest around 54.5 million shares in Lundin Petroleum for a total consideration of around USD 1.56 billion and to acquire 2.6% of the development project Johan Sverdrup for a cash consideration of USD 910 million.  

Equinor ASA is a global energy company with more than 20,000 employees and business in more than 30 countries. Equinor is the largest oil and gas operator in Norway, one of the largest offshore operators globally and has a growing portfolio of renewable assets in wind and solar power.
 
Vinge’s team consisted of Dain Hård Nevonen, David Andersson, Johan Karlsson och Anna Grigorian.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025